Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 4/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 2/20 | 0.38 |
| ▸ | AKT2 | P31751 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2978431 | 0.85 | AKT1 (0.49) | MAPTALDH1A1KDM4EHPGDGAA | |
| SCHEMBL3808855 | 0.82 | AKT1 (0.51) | MAPTALDH1A1KDM4EHPGDGAA | |
| SCHEMBL3708083 | 0.81 | ADORA2A (0.51) | ALDH1A1ADORA2ARAB9ANPC1TNK2 | |
| SCHEMBL2972057 | 0.78 | KMT2A (0.46) | MAPTALDH1A1KDM4EHPGDRAB9A | |
| SCHEMBL1428218 | 0.76 | AKT1 (0.62) | MAPTALDH1A1KDM4EHPGDGAA | |
| SCHEMBL2970268 | 0.74 | ADORA2A (0.41) | MAPTALDH1A1KDM4EHPGDGAA | |
| SCHEMBL2978903 | 0.73 | MAPT (0.42) | MAPTALDH1A1KDM4EHPGDGAA | |
| SCHEMBL2977680 | 0.72 | AKT1 (0.48) | MAPTALDH1A1KDM4EHPGDGAA | |
| SCHEMBL18104259 | 0.71 | MAPT (0.63) | MAPTALDH1A1KDM4EHPGDGAA | |
| SCHEMBL13256347 | 0.71 | KMT2A (0.40) | MAPTALDH1A1KDM4EHPGDADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2396330-B1 | FUSED PYRIMIDINES | BAYER IP GMBH (DE) | 2016-04-06 | — | — | EP | disclosed |
| EP-2396330-B1 | FUSED PYRIMIDINES | BAYER IP GMBH (DE) | 2016-04-06 | — | — | EP | disclosed |
| US-8957064-B2 | Fused pyrimidines | BAYER INTELLECTUAL PROPERTY GMBH (US) | 2015-02-17 | — | — | US | disclosed |
| US-8957064-B2 | Fused pyrimidines | BAYER INTELLECTUAL PROPERTY GMBH (US) | 2015-02-17 | — | — | US | disclosed |
| US-8957064-B2 | Fused pyrimidines | BAYER INTELLECTUAL PROPERTY GMBH (US) | 2015-02-17 | — | — | US | disclosed |
| US-8614218-B2 | Fused bicyclic pyrimidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-12-24 | — | — | US | disclosed |
| US-20130317002-A1 | FUSED PYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-11-28 | — | — | US | disclosed |
| EP-2188291-B1 | FUSED BICYCLIC PYRIMIDINES | Bayer Pharma AG (DE) | 2012-09-19 | — | — | EP | disclosed |
| EP-2396330-A1 | FUSED PYRIMIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010091808-A1 | FUSED PYRIMIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010091808-A1 | FUSED PYRIMIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-19 | — | — | WO | disclosed |
| US-7776864-B2 | Fused bicyclic pyrimidines | BAYER SCHERING PHARMA AG (DE) | 2010-08-17 | — | — | US | disclosed |
| US-20100184782-A1 | FUSED BICYCLIC PYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2010-07-22 | — | — | US | disclosed |
| US-20090137607-A1 | FUSED BICYCLIC PYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
| EP-2050748-A1 | Novel fused pyrimidines | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137607-A1 | FUSED BICYCLIC PYRIMIDINES | PIK3CA, TYMS, MTOR | MAPT 616/4885ALDH1A1 3182/4885KDM4E 3173/4885 |
| US-20130317002-A1 | FUSED PYRIMIDINES | PIK3CA, MTOR, TYMS | MAPT 393/4885ALDH1A1 3442/4885KDM4E 3716/4885 |
| US-20100184782-A1 | FUSED BICYCLIC PYRIMIDINES | PIK3CA, TYMS, MTOR | MAPT 616/4885ALDH1A1 3182/4885KDM4E 3173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.